These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy. Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413 [TBL] [Abstract][Full Text] [Related]
3. Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer. ; Mari A; D'Andrea D; Kimura S; Resch I; Shariat SF; Klatte T Urol Int; 2018; 101(2):197-200. PubMed ID: 30089304 [TBL] [Abstract][Full Text] [Related]
4. Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer. Mayr R; Gierth M; Zeman F; Reiffen M; Seeger P; Wezel F; Pycha A; Comploj E; Bonatti M; Ritter M; van Rhijn BWG; Burger M; Bolenz C; Fritsche HM; Martini T J Cachexia Sarcopenia Muscle; 2018 Jun; 9(3):505-513. PubMed ID: 29479839 [TBL] [Abstract][Full Text] [Related]
5. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Psutka SP; Carrasco A; Schmit GD; Moynagh MR; Boorjian SA; Frank I; Stewart SB; Thapa P; Tarrell RF; Cheville JC; Tollefson MK Cancer; 2014 Sep; 120(18):2910-8. PubMed ID: 24840856 [TBL] [Abstract][Full Text] [Related]
6. Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Lyon TD; Frank I; Takahashi N; Boorjian SA; Moynagh MR; Shah PH; Tarrell RF; Cheville JC; Viers BR; Tollefson MK Clin Genitourin Cancer; 2019 Jun; 17(3):216-222.e5. PubMed ID: 31060857 [TBL] [Abstract][Full Text] [Related]
7. Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer. Almarzouq A; Kool R; Al Bulushi Y; Marcq G; Souhami L; Cury FL; Brimo F; Chong J; Kassouf W Urol Oncol; 2022 May; 40(5):194.e15-194.e22. PubMed ID: 34862117 [TBL] [Abstract][Full Text] [Related]
8. Decrease in skeletal muscle index 1 year after radical cystectomy as a prognostic indicator in patients with urothelial bladder cancer. Ha YS; Kim SW; Kwon TG; Chung SK; Yoo ES Int Braz J Urol; 2019; 45(4):686-694. PubMed ID: 30901172 [TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254 [TBL] [Abstract][Full Text] [Related]
11. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860 [TBL] [Abstract][Full Text] [Related]
12. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer. Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780 [TBL] [Abstract][Full Text] [Related]
13. Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma. Granfors T; Tomic R; Ljungberg B Scand J Urol Nephrol; 2009; 43(4):293-9. PubMed ID: 19363744 [TBL] [Abstract][Full Text] [Related]
14. Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer. Mayr R; Fritsche HM; Zeman F; Reiffen M; Siebertz L; Niessen C; Pycha A; van Rhijn BWG; Burger M; Gierth M World J Urol; 2018 Aug; 36(8):1201-1207. PubMed ID: 29520591 [TBL] [Abstract][Full Text] [Related]
15. Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis. García-Perdomo HA; Montes-Cardona CE; Guacheta M; Castillo DF; Reis LO World J Urol; 2018 Dec; 36(12):1997-2008. PubMed ID: 29943218 [TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083 [TBL] [Abstract][Full Text] [Related]
17. Bladder sparing surgery in high-grade bladder cancer. Yakovlev PG; Klyushin DA; Vereshchako RI Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149 [TBL] [Abstract][Full Text] [Related]
18. Effect of neoadjuvant chemotherapy in patients undergoing radical cystectomy for muscle-invasive bladder cancer: a retrospective, multi-institutional study. Nitta M; Kuroda S; Nagao K; Higure T; Zakoji H; Miyakita H; Usui Y; Hasegawa M; Kawamura Y; Shoji S; Miyajima A Jpn J Clin Oncol; 2020 Jan; 50(1):73-79. PubMed ID: 31612911 [TBL] [Abstract][Full Text] [Related]